Furthermore, our analysis of Orien/cBioPortal data reveals a prognostic implication of LY6E amplification in ovarian cancer, suggesting its potential utility as a biomarker for patient stratification and therapeutic decisions. The gene discussed is LY6E; the disease is ovarian carcinoma.